HCC1588 Cells

HCC1588 is a human breast cancer cell line derived from a patient with primary breast carcinoma and is classified within the basal-like subtype of breast cancer. This cell line is representative of triple-negative breast cancer (TNBC), lacking expression of estrogen receptor (ER), progesterone receptor (PR), and HER2 amplification. As a basal-like model, HCC1588 exhibits molecular characteristics associated with aggressive tumor behavior, including high proliferative capacity, genomic instability, and enrichment of gene expression programs linked to epithelial-to-mesenchymal transition and stem-like phenotypes.

Molecular profiling of large cancer cell line panels has demonstrated that breast cancer cell lines such as HCC1588 contribute to the diversity of genomic and transcriptomic alterations used to model tumor heterogeneity and therapeutic response. Across integrated pharmacogenomic studies, cancer cell lines recapitulate key oncogenic alterations observed in primary tumors and are routinely used to correlate genetic features with drug sensitivity across hundreds of compounds. In addition, standardized annotation and authentication frameworks emphasize the importance of consistent molecular characterization, including short tandem repeat and SNP profiling, to ensure reproducibility and accurate lineage classification in widely used models such as HCC1588.

Functionally, HCC1588 is frequently employed in studies investigating mechanisms of tumor progression, DNA damage response, and resistance to chemotherapeutic and targeted agents in triple-negative breast cancer. Its basal-like phenotype and lack of hormone receptor signaling make it particularly valuable for evaluating novel therapeutic strategies aimed at aggressive, treatment-refractory breast cancer subtypes.